Medicine. The need for a global HIV vaccine enterprise.
Klausner RD., Fauci AS., Corey L., Nabel GJ., Gayle H., Berkley S., Haynes BF., Baltimore D., Collins C., Douglas RG., Esparza J., Francis DP., Ganguly NK., Gerberding JL., Johnston MI., Kazatchkine MD., McMichael AJ., Makgoba MW., Pantaleo G., Piot P., Shao Y., Tramont E., Varmus H., Wasserheit JN.
A new collaborative model of research is needed to increase resources, to prioritize the R (ii) to increase the pace, reduce the overlap, and more systematically explore the elements of and delivery systems for vaccines; (iii) to use common standards for the prompt comparative testing of vaccine candidates; (iv) to expand resources for manufacturing vaccine candidates to speed their use in human trials; and (v) to increase the capacity for international clinical trials and to focus this effort toward quickly measuring the effectiveness of vaccine protection as prototype vaccine candidates are identified.